Hepatocellular Carcinoma (HCC)

Oncology·MeSH: Carcinoma, Hepatocellular

Prevalence

12.0 / 100K

Incidence

8.6 / 100K/yr

14 drugs in development·11 companies·17 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
CABOMETYX	EXELIXIS, INC. (EXEL)

Phase 3(3)

Drug	Company
amezalpat	Tempest Therapeutics, Inc. (TPST)
Pumitamig	BRISTOL MYERS SQUIBB CO (BMY)
tpst-1120	Tempest Therapeutics, Inc. (TPST)

Phase 2(5)

Drug	Company
CTLA-4 Antibody	Crinetics Pharmaceuticals, Inc. (CRNX)
incb062079	Incyte Corp. (INCY)
mFOLFOX/FOLFIRI	KYNTRA BIO INC. (KYNB)
Rencofilstat (formerly CRV431; CPI-431-32)	Hepion Pharmaceuticals, Inc. (CTRVP)
rencofilstat (formerly CRV431)	Hepion Pharmaceuticals, Inc. (CTRVP)

Phase 1(2)

Drug	Company
afp-tcr-t	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
Monoclonal antibody BAT6026	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 1/Phase 2(3)

Drug	Company
otx-2002	Omega Therapeutics, Inc. (OMGA)
ryz801	RayzeBio, Inc. (RYZB)
will receive hh-009	China Health Industries Holdings, Inc. (CHHE)

BioSniper tracks 14 drugs in development for Hepatocellular Carcinoma (HCC) across 11 companies.

There are 17 clinical trials targeting Hepatocellular Carcinoma (HCC) tracked by BioSniper.

The estimated prevalence of Hepatocellular Carcinoma (HCC) is approximately 12.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.